Korea Patent Injunction vs Main Action Break-Even Calculator

Compare a Korean patent main action with conditional injunction-granted and injunction-denied paths using sales timing, margin loss, procedure cost, security funding, liquidity, and break-even month.

1. Sales, margin, and at-risk inventory

This does not assume infringement. Align the source period for units, margin, and substitution.

units/mo

User assumption supported by sales, shipment, purchase, or market records

KRW/unit

Contribution margin from one incremental sale, not revenue

%

Share of each accused unit assumed to displace a right-holder sale

units

Do not duplicate units already counted in monthly volume.

%

A conditional user scenario, not a forecast of the order or enforcement

2. Comparison horizon and present value

These periods do not forecast court timing or success. Run separate conservative, base, and upside assumptions.

months
months

Month after filing when effect is assumed to begin

months

Comparison assumption, not a forecast of judgment, finality, or enforcement

%

Present-value assumption for future margin loss, not a statutory rate

3. Main-action and incremental injunction cost

Separate common main-action cost from incremental injunction work and compare estimates with the same scope.

KRW

Common estimate assuming the main action continues in all paths

KRW
KRW

Claim comparison, testing, or technical opinion cost also incurred if denied

KRW

4. Security, guarantee, and available cash

Security principal is separate from economic cost; only financing cost on its cash portion affects benefit.

KRW

Value to confirm from an actual order or advice, not a statutory rate

%
%
months
KRW
KRW

Used for cumulative exposure only; it does not replace a payment-month schedule.

5. Evidence checklist before review

A check does not establish infringement, validity, preservation need, or sufficient proof. Missing groups remain below.

2026 user-scenario result

Sales-timing and cost comparison, not a legal outcome

Net benefit if granted

KRW 305,161,358

Conditional result without a grant probability

Break-even month

Month 5 after filing

2 months after assumed decision

Accelerated-relief window

15 months

18-month comparison horizon

Maximum cumulative cash gap

KRW 244,000,000

Largest gap across the three paths

Monthly loss, inventory, and timing breakdown

Monthly right-holder margin loss

KRW 35,000,000

Monthly avoided loss

KRW 24,500,000

At-risk inventory margin loss

KRW 14,000,000

Avoided inventory loss

KRW 9,800,000

Pre-decision exposure

3 months

Avoided loss present value

KRW 361,161,358

Incremental injunction cost

KRW 56,000,000

Locked cash security

KRW 100,000,000

Three-path comparison

The denied path assumes denial before security or enforcement and adds only application and technical-review cost. Cumulative cash exposure is not a payment-month peak.

Present-value burden and nominal cash exposure for main-only, granted, and denied assumptions
PathLoss PVProcedure costEconomic burden PVNominal burdenCumulative cash exposureCash gap
Main action only assumptionKRW 620,095,004KRW 60,000,000KRW 680,095,004KRW 704,000,000KRW 704,000,000KRW 204,000,000
Injunction added / granted assumptionKRW 258,933,646KRW 116,000,000KRW 374,933,646KRW 382,700,000KRW 482,700,000KRW 0
Injunction added / denied assumptionKRW 620,095,004KRW 100,000,000KRW 720,095,004KRW 744,000,000KRW 744,000,000KRW 244,000,000

Security-principal sensitivity

This mechanically compares 50%, 100%, and 150% of entered security. It does not predict a court-ordered amount or cash share.

Financing cost, break-even month, net benefit, and cash gap at 50%, 100%, and 150% of entered security
Security factorPrincipalLocked cashFinancing costBreak-even monthGranted net benefitCash gap
50%KRW 100,000,000KRW 50,000,000KRW 4,000,000Month 5 after filingKRW 309,161,358KRW 0
100%KRW 200,000,000KRW 100,000,000KRW 8,000,000Month 5 after filingKRW 305,161,358KRW 0
150%KRW 300,000,000KRW 150,000,000KRW 12,000,000Month 6 after filingKRW 301,161,358KRW 36,700,000

Interpretation warnings

  • This result does not decide patent validity, infringement, claim scope, preservation need, grant likelihood, or the merits.
  • At-risk inventory is entered. Check that the same expected units are not already included in monthly volume.
  • Security principal is excluded from economic cost, while its cash portion is included as locked cash exposure.
  • At least one path exceeds available cash over the horizon. Build a separate payment-month liquidity schedule.
  • Some evidence groups remain unconfirmed. Take the result and missing list to case-specific review.

Unconfirmed evidence

  • I checked the register, term, claims, specification, amendments, and licence scope.
  • I checked accused-product samples, catalogues, purchase records, and a claim comparison.
  • I checked prior art, invalidity or amendment proceedings, and validity-risk review materials.
  • I checked monthly units, capacity to sell, unit margin, and substitution-rate support.
  • I checked at-risk inventory, market horizon, timing assumptions, and unit-count duplication.
  • I checked main-action, injunction, technical, enforcement, security, guarantee, and funding estimates.

Legal notice

This Korea-based planning tool reflects Patent Act and Civil Execution Act boundaries checked on August 30, 2026. Monetary benefit is not patent validity, infringement, preservation need, or grant likelihood. Have Korean patent counsel review the claims, validity material, counterparty harm, security, and main-action plan.

Related calculators

Decision preparation for a patent owner

The economic value of an injunction begins with time, not a damages award

A Korean main action is the central proceeding for fully contesting infringement, validity defenses, injunctive relief, and damages.
Yet a later judgment may not restore sales opportunities lost while an accused product remains on the market.
This calculator puts that timing problem into a transparent monthly model and compares a main-action-only path with two conditional injunction paths.

The granted path assumes that an interim order reduces accused sales by the percentage you enter after an assumed decision month.
The denied path assumes denial before security or enforcement and adds the application and technical-review costs to the same loss path as the main action.
Neither path is a forecast, and the calculator never invents a grant probability or converts the arithmetic into a legal recommendation.

Main action only

Monthly margin loss and one at-risk inventory loss continue until the earlier of the assumed merits judgment and the remaining market life.

Injunction granted assumption

Pre-decision loss remains, while post-decision monthly and inventory loss fall only by the user-entered sales-reduction percentage.

Injunction denied assumption

The main-only loss continues and the application plus technical-review cost becomes the conditional downside.

Korean legal boundaries checked for the 2026 model

Patent Act Article 126 provides the statutory starting point for a patent owner or exclusive licensee to seek prevention or cessation of infringement and measures such as disposal of infringing articles or removal of facilities used for infringement.
It does not make this calculator capable of deciding patent term, claim construction, infringement, ownership, licence scope, exhaustion, or the proper breadth of an order.

Civil Execution Act Article 300 addresses provisional dispositions fixing a temporary position where necessary to avoid substantial harm or prevent imminent danger in a disputed legal relationship.
Article 301 applies provisional-seizure procedure mutatis mutandis, Article 280 supplies the security framework, and Article 304 supplies the hearing framework.
Articles 287 and 288 matter because an injunction application cannot responsibly be budgeted as a shortcut isolated from a main action and possible cancellation issues.

Official Korean legal sources and boundaries used for the patent injunction comparison
AuthorityPlanning boundary reflected hereWhat the tool does not decide
Patent Act Article 126Statutory basis for seeking prevention or cessation and necessary measuresValidity, infringement, ownership, scope, or remedy wording
Civil Execution Act Articles 300 and 301Temporary-position and preservation-need frameworkSubstantial harm, imminent danger, urgency, timing, or grant
Civil Execution Act Articles 280, 287, 288, and 304Security, main-action order, cancellation, and hearing context for budget inputsSecurity amount, cash share, hearing schedule, or procedural outcome
Supreme Court 2006Ma907Careful review of both parties' gains and losses, merits outlook, and related circumstancesWhether the cited case controls a current dispute or whether invalidity is likely

This is not a Patent Act Article 128 damages calculator

Patent Act Article 128 contains rules relevant to measuring damages for infringement, but this page does not calculate an adjudicated damages amount for past conduct.
Unit margin and substitution rate are user assumptions for comparing the economic value of earlier sales interruption.
They are not court findings on lost profit, contribution, reasonable royalty, infringer profit, or enhanced damages.

Why the decision delay and market horizon must be separate

An injunction does not create economic relief on the filing date in this model.
All monthly loss through the assumed decision month remains in the granted scenario.
Avoided monthly loss begins only after that point and ends at the earlier of the assumed main judgment month and the remaining commercial life of the product or market.

A main judgment assumed at month 18 therefore does not create an 18-month comparison if the market is expected to disappear at month 8.
The horizon becomes 8 months.
If the assumed injunction decision is month 8 or later, the accelerated-relief window becomes zero and the tool reports no sales-timing benefit within that horizon.

This is an arithmetic consequence, not a legal conclusion that provisional relief lacks value.
Hearing dates, service, technical presentations, evidence preservation, settlement discussions, amendments, invalidity proceedings, enforcement, and court workload can all change the actual sequence.
Replace every timing default with a dated case plan reviewed by Korean patent counsel.

Timeline formulas

Comparison horizon = the smaller of remaining market months and assumed main-judgment months.
Pre-decision exposure = the smaller of assumed injunction-decision months and the comparison horizon.
Accelerated-relief window = comparison horizon minus pre-decision exposure, floored at zero.

Prepare inputs from ledgers, sales evidence, and actual quotes

Monthly accused units and unit margin

Enter only the monthly accused volume that can be supported by records, samples, channel data, lawful discovery, or a clearly documented inference.
Unit margin should represent the right holder's incremental contribution margin from one additional unit, not the accused seller's revenue and not the right holder's full selling price.
Check production capacity, inventory, channel access, customer preference, and price positioning before treating a unit as substitutable.

Lost-sales rate and post-order reduction

The lost-sales rate is the share of accused units assumed to return as right-holder sales if the accused competition disappears.
The post-order sales-reduction rate allows for order scope, enforcement delay, channel inventory, design-arounds, exports, substitutes, or residual conduct.
Both percentages matter because the model first estimates displaced right-holder margin and then estimates how much of that displacement an order would actually stop.

At-risk inventory without double counting

At-risk inventory is a one-time quantity expected to be sold within the horizon and potentially affected at the assumed decision point.
Do not enter the same stock if it is already embedded in the monthly accused-unit forecast.
Keep a model, lot, holder, location, expected sell-through date, and source schedule so an adviser can test whether the one-time line is independent.

Procedure cost and security liquidity

Separate main-action cost from injunction application, patent-attorney or technical review, enforcement, guarantee premium, and funding cost.
A potentially returnable security principal is not treated as an immediate economic expense.
Its cash portion is shown as locked liquidity, while the funding cost of that cash becomes an economic cost over the entered security period.

Calculation sequence and present-value treatment

The model rounds to whole Korean won and converts the annual decision discount rate into an effective monthly rate.
That discount rate is not a Korean statutory interest rate, a litigation-delay rate, or a finding about recoverable interest.
It is a user-entered capital-cost assumption used only to compare future monthly losses at a common valuation date.

  1. Monthly margin loss equals monthly accused units multiplied by right-holder unit margin and the lost-sales rate.
  2. Monthly avoided loss equals monthly margin loss multiplied by the post-order sales-reduction rate.
  3. Inventory margin loss and avoided inventory loss use the same two rates and are discounted once at the assumed decision month.
  4. Denied incremental cost equals application cost plus technical-review cost under the simplified denial path.
  5. Granted incremental cost adds enforcement cost, guarantee premium, and cash-security funding cost.
  6. Conditional granted net benefit equals main-only present-value economic burden minus granted-path present-value economic burden.
  7. The break-even calendar month is the first month when discounted avoided inventory and monthly loss cumulatively reach granted incremental cost.

Economic cost and locked cash answer different questions

Security funding cost = security principal multiplied by cash-security share, annual funding rate, and security months divided by twelve.
Cumulative cash exposure adds the locked cash-security principal to nominal loss and procedure spending.
A path can therefore show positive economic benefit but still exceed available cash.
Build a separate payment-month treasury schedule before filing because this tool reports cumulative exposure, not the true peak by payment date.

Worked example with reproducible default inputs

The defaults are synthetic arithmetic examples, not Korean market averages, typical court values, or recommended assumptions.
Assume 5,000 accused units per month, KRW 20,000 of right-holder contribution margin per unit, and a 35 percent lost-sales rate.
Monthly right-holder margin loss is KRW 35,000,000.
A separate 2,000-unit at-risk inventory produces KRW 14,000,000 of inventory margin loss.

Assume an order would reduce relevant sales by 70 percent.
Monthly avoided loss is KRW 24,500,000 and avoided inventory loss is KRW 9,800,000.
A 24-month remaining market and an 18-month assumed main judgment create an 18-month comparison horizon.
A decision at month 3 leaves 15 accelerated-relief months.

Use a 5 percent annual discount rate, KRW 60,000,000 of main-action cost, KRW 30,000,000 of application cost, KRW 10,000,000 of technical-review cost, and KRW 5,000,000 of enforcement cost.
Enter KRW 200,000,000 of assumed security, a 50 percent cash share, an 8 percent annual cash funding rate, a 12-month security period, and KRW 3,000,000 of guarantee and setup fees.
Locked cash is KRW 100,000,000, funding cost is KRW 8,000,000, and granted incremental procedure cost is KRW 56,000,000.

Worked example comparing the three conditional paths
Conditional pathEconomic burden PVNominal burdenCumulative cash exposureInterpretation
Main action onlyKRW 680,095,004KRW 704,000,000KRW 704,000,000Horizon loss plus main-action cost
Injunction granted assumptionKRW 374,933,646KRW 382,700,000KRW 482,700,000Post-decision reduction plus security funding
Injunction denied assumptionKRW 720,095,004KRW 744,000,000KRW 744,000,000Main-only loss plus application and technical cost

Conditional net benefit

KRW 305,161,358

This assumes grant and is not probability weighted.

Break-even timing

Month 5 after filing

This is two months after the assumed decision.

Maximum cash gap

KRW 244,000,000

Largest of three paths against KRW 500,000,000 available cash.

Security sensitivity is a liquidity stress test, not a court forecast

Korean law does not supply one fixed security amount or universal cash-security percentage for every patent injunction.
The calculator therefore changes only the entered security principal to 50, 100, and 150 percent while keeping the entered cash share, funding rate, and security months unchanged.
The purpose is to identify whether funding cost, break-even timing, or liquidity changes materially around the working estimate.

Security-principal sensitivity for the worked example
Entered security factorGranted incremental costConditional net benefitBreak-even monthCash gap
50 percentKRW 52,000,000KRW 309,161,358Month 5KRW 0
100 percentKRW 56,000,000KRW 305,161,358Month 5KRW 0
150 percentKRW 60,000,000KRW 301,161,358Month 6KRW 36,700,000

Ask counsel and a guarantee provider whether any estimate assumes cash, a guarantee bond, a combination, staged security, or later substitution.
Record the quote date, premium basis, collateral requirement, credit line usage, cancellation terms, and expected release date.
None of those commercial terms is supplied by statute or inferred by the calculator.

A seven-step review workflow

  1. Freeze the right and accused-product scope
    Match register status, term, claims, specification, amendments, licences, models, methods, territories, and relevant dates.
  2. Build a support sheet for monthly loss
    Separate accused volume, right-holder margin, capacity to supply, channel access, customer substitution, and the source for each assumption.
  3. Replace timing defaults with a case calendar
    Mark service, hearing, technical briefing, expected decision, main-action milestones, product replacement, patent expiry, and market end.
  4. Split common and incremental professional cost
    Keep main-action spending out of the injunction-only subtotal and identify technical, translation, experiment, inspection, and enforcement work.
  5. Model security as both funding cost and locked liquidity
    Use actual cash-share and guarantee quotes, then create a separate payment-date treasury schedule.
  6. Save conservative, base, and upside cases
    Change lost-sales rate, sales reduction, decision month, market horizon, security, and funding rate without hiding which variable changes the answer.
  7. Take the result and source bundle to Korean counsel
    The evidence checklist, input date, record owner, and scenario notes are more useful than an isolated net-benefit number.

Practical scenarios for using the comparison

Seasonal goods and short product cycles

A later merits judgment may arrive after the selling season or model generation has ended.
Shorten the market horizon and move the decision month one or two months at a time to see when the conditional benefit disappears.
This can clarify which commercial timing records and procedural milestones deserve immediate attention without proving legal urgency.

Components and manufacturing processes

Accused component volume may not equal finished-product displacement.
Document conversion ratios, claim-relevant steps, customer alternatives, design-around timing, and right-holder supply capacity outside the calculator.
Enter only the final monthly unit assumption that can be explained consistently with that support sheet.

A cash-constrained patent owner

A positive conditional economic benefit does not fund security or professional fees.
Compare the 150 percent security row with available cash and then discuss cash deposit, bond availability, credit limits, collateral, shareholder funding, and working-capital protection.
The cumulative gap is a screening signal, not a bankable draw schedule.

Evaluating a proposed standstill or licence

A proposal may limit volume, permit inventory sell-through, set a design-around date, or offer a licence before a decision.
Translate only its expected timing and sales-reduction effect into a separate scenario.
Confidentiality, release, no-challenge, no-suit, foreign proceedings, royalty tax, audit rights, and non-monetary terms remain outside this model.

Six evidence bundles to review before advice

  • Patent-right scope: register, term, annuities, claims, specification, prosecution and amendment history, licences, and ownership chain.
  • Infringement comparison: lawfully obtained samples, catalogues, purchase records, process information, model mapping, and a claim chart.
  • Validity review: prior art, invalidity or amendment proceedings, family prosecution, expert analysis, and unresolved search limitations.
  • Sales and margin: monthly units, prices, variable cost, capacity, stock, channel records, customer switching, and a dated substitution rationale.
  • Inventory and timeline: stock holder, location, lot, sell-through, market end, patent expiry, decision plan, main-action plan, and duplication check.
  • Cost and security: main-action and application engagement scopes, technical and enforcement quotes, security assumptions, guarantee terms, funding rate, and available cash.

A checked box is not an evidence ruling

Marking a bundle confirmed does not establish lawful collection, authenticity, admissibility, weight, infringement, validity, or preservation need.
Preserve originals, collection dates, authors, custody, versions, and access limits.
Trade secrets, personal information, communications, competitor sampling, employee material, and cross-border data may require separate Korean legal review.

Interpretation mistakes to avoid

  • Do not call conditional granted net benefit an expected value or attach an unsupported grant percentage.
  • Do not use accused revenue as right-holder contribution margin or assume sales beyond right-holder capacity.
  • Do not count the same units in both monthly volume and at-risk inventory.
  • Do not assume a decision instantly eliminates all sales, recalls all channel inventory, or prevents every design-around.
  • Do not expense the full potentially returnable security principal, and do not ignore its liquidity lock.
  • Do not duplicate main-action cost inside injunction-only application or technical-review cost.
  • Do not confuse present-value economic burden with the actual peak cash need by payment month.
  • Do not assume the model includes tax, accounting provisions, adverse-security claims, cancellation, suspension, appeal, insolvency, foreign relief, or collection.
  • Do not use Patent Act Article 128 as a reason to label these planning losses adjudicated damages.
  • Do not let a large arithmetic result replace claim construction, validity review, proportionality, or counterparty-harm analysis.

Frequently asked questions

Does a positive net benefit mean the patent owner should file

No.
It means only that the conditional granted path has a lower economic burden than the main-only path under the entered timing, sales, cost, and security assumptions.
Patent validity, infringement, preservation need, counterparty harm, undertaking or security, enforcement, business relationships, and remedies require case-specific Korean advice.

Why is there no grant-probability input

Claim construction, accused features, prior art, amendment posture, both parties' harm, evidence quality, procedural developments, and judicial assessment make a universal objective percentage inappropriate.
The calculator keeps the main-only, granted, and denied paths separate so a legal opinion is not silently converted into a made-up probability.

What security amount should I enter

There is no universal statutory amount or cash percentage for every case.
Use a case-specific working estimate from counsel, relevant orders if appropriately comparable, and an actual guarantee or financing quote.
Treat the 50, 100, and 150 percent rows only as sensitivity checks, not predictions of what a Korean court will order.

Where do I enter later damages recovery

You do not enter it in this tool.
A future damages recovery may affect both litigation strategies and depends on proof, legal measurement, offsets, tax, enforceability, solvency, timing, and collection.
Keep that analysis separate from the narrower value of accelerating sales interruption.

Does no break-even month mean provisional relief has no value

No.
It means discounted monetary avoided loss does not reach granted incremental cost within the entered comparison horizon.
Brand positioning, price discipline, evidence preservation, channel relationships, negotiation leverage, deterrence, and other non-monetary considerations are outside the arithmetic.

Can I submit the result directly to a court

No.
It is an internal planning calculation, not an expert report, pleading, affidavit, evidence schedule, accounting opinion, damages analysis, or legal submission.
Korean counsel must review the underlying records, lawful collection, evidentiary purpose, methodology, wording, and relevance before deciding whether any derived schedule belongs in a filing.

Official sources and update date

The legal-source review date is August 30, 2026, represented in the data model as 2026-08-30.
The Patent Act source is Law ID 001455, MST 279827, effective November 11, 2025, with Articles 126 and 128 reviewed for the boundaries described above.
The Civil Execution Act source is Law ID 009290, MST 268837, effective February 1, 2026, with Articles 280, 287, 288, 300, 301, and 304 reviewed.
The precedent source is Supreme Court case 2006Ma907, decided June 4, 2007, official precedent ID 68821.

A later amendment, new en banc or Supreme Court decision, court practice, special forum rule, or case-specific order can change the relevant analysis.
Recheck all official sources as of the filing date and record which statutory version counsel used.
The model intentionally contains no fixed statutory decision period, professional fee, security amount, sales-reduction rate, market life, or margin benchmark.

Preserve the assumptions before relying on the result

Patent scope, product life, customer substitution, decision timing, enforcement effect, security structure, and funding terms can change the answer materially.
Save a conservative, base, and upside input set with an as-of date, source record, preparer, reviewer, and explanation for every percentage.
Deliver the result together with the claim chart, validity material, sales ledger, margin bridge, inventory schedule, case calendar, professional quote, and security quote.

The most useful output is not one attractive number.
It is a visible map of which factual, legal, operational, and funding assumptions could change the filing decision and which evidence remains unconfirmed.
Use that map to ask better questions of Korean patent counsel, a patent attorney, finance staff, and treasury advisers.

This Korea-focused calculator provides general planning information only.
It is not legal, patent, accounting, tax, financing, valuation, or investment advice and does not predict validity, infringement, preservation need, security, grant, enforcement, damages, settlement, or case outcome.